Hutchmed (China) Limited 24 June 2024 HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda ...
Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with auto ...
Hutchmed (China) Limited 17 June 2024 Press Release HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology...
Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its men ...
Hutchmed (China) Limited 07 June 2024 Press Release HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with...
Hutchmed (China) Limited 03 June 2024 Press Release HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine ...
Hutchmed (China) Limited 31 May 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ — Friday, May 31, 2024: HUTCHMED...
Hutchmed (China) Limited 24 May 2024 Press Release HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting Hong Kong, Shanghai...
Ltd - Hong Kong-headquartered biopharmaceutical company - Chair Simon To retires from his role as chair, succeeded by ...
Hutchmed (China) Limited 17 May 2024 HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board...
Hutchmed (China) Limited 17 May 2024 Press Release HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy...
Hutchmed (China) Ltd on Tuesday announced upcoming trials for two of its pipeline cancer treatments, both of which it ...
Hutchmed (China) Limited 14 May 2024 Press Release HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab...
Hutchmed (China) Limited 14 May 2024 Press Release HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients...
Hutchmed (China) Limited 10 May 2024 Annual General Meeting held on May 10, 2024 - Poll Results Hong Kong, Shanghai, & Florham Park...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads